央视网消息：农业农村部最新数据显示，10月份全国菜篮子指数为133.2，环比下降2.62个点，其中，蔬 菜价格较上月小幅回落。 农业农村部：10月份蔬菜价格较上月小幅回落 10月份，农业农村部监测的28种蔬菜全国平均批发价为每公斤5.9元，环比下降2.5%，同比上涨21.4%。 分品种看，环比价格17种下降，11种上涨，菠菜、油菜、黄瓜价格环比降幅超过10%。 中国农业科学院农业信息研究所副研究员 张晶：10月份全国蔬菜价格小幅回落主要原因是10月份天气 条件有利于田间秋茬蔬菜生长，露地蔬菜大量上市，设施蔬菜供应逐步恢复，各地蔬菜产能有所增加。 专家表示，目前夏秋蔬菜衔接期间价格的高位震荡已经度过，尤其是一些生长周期较长的蔬菜，在10月 中下旬相继完成产地转换，西红柿等部分品种供应偏紧的状况逐步得到缓解，加上耐储的萝卜、甘蓝等 品种量足价稳，拉动菜价整体回落。 张晶：预计后期蔬菜价格将保持季节性下行，前期推迟上市的品种逐步恢复，设施生产的黄瓜、西红 柿、辣椒等陆续上市，后期的蔬菜供应量将进一步增加，秋菜的在途损耗少、保鲜成本降低，菜价将继 续回落。 北京：供应增加 部分蔬菜价格降幅明显 在北京，近期随着产地供 ...

证券研究报告·公司点评报告·医药商业 老百姓（603883） 2024 年三季报点评：利润受新店爬坡及基数 影响短期承压，火炬项目持续提利 2024 年 11 月 01 日 买入（维持） | --- | --- | --- | --- | --- | --- | |------------------------------|--------|--------|---------|--------|----------| | 盈利预测与估值 [Table_EPS] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业总收入（百万元） | 20176 | 22437 | 23459 | 25914 | 28567 | | 同比（ % ） | 28.54 | 11.21 | 4.55 | 10.46 | 10.24 | | 归母净利润（百万元） | 784.96 | 929.02 | 825.10 | 950.84 | 1,085.84 | | 同比（ % ） | 17.29 | 18.35 | (11.19) | 15.24 | 14.20 | | EPS- 最新摊薄（元 ...

公 司 研 究 医 药 生 物 老百姓 沪深300 公 司 简 评 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 | --- | --- | |---------------------------|-------------| | | | | 数据日期 Table_cominfo] | 2024/10/31 | | 收盘价 | 16.07 | | 总股本 ( 万股 ) | 76,023 | | 流通 A 股 /B 股 ( 万股 ) | 75,792/0 | | 资产负债率 (%) | 64.41% | | 市净率 ( 倍 ) | 1.62 | | 净资产收益率 ( 加权 ) | 9.14 | | 12 个月内最高 / 最低价 | 36.90/11.90 | [Table_Reportdate] 2024年11月01日 [Table_invest] 买入（维持） 报告原因：业绩点评 [证券分析师 Table_Authors] 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 w ...

公 司 报 告 公 司 季 报 点 评 证 券 研 究 报 告 2024年11月01日 医药 老百姓(603883.SH) 业绩承压，提升利润率为经营重点 推荐 ( 维持) 平安观点： ■ 股价:16.07元 | --- | --- | |------------------------|--------------------------------| | 行业 | 医药 | | 公司网址 | www.lbxdrugs.com | | 大股东 / 持股 | 老百姓医药集团有限公司 /26.12% | | 实际控制人 | 谢子龙 , 陈秀兰 | | 总股本 ( 百万股 ) | 760 | | 流通 A 股 ( 百万股 ) | 758 | | 流通 B/H 股 ( 百万股 ) | | | 总市值 ( 亿元 ) | 122 | | 流通 A 股市值 ( 亿元 ) | 122 | | 每股净资产 ( 元 ) | 9.16 | | 资产负债率 (%) | 64.4 | | 行情走势图 | | | | | 证券分析师 | --- | |------------------------| | | | 投资咨询资格编号 | ...

f 隔证券 医药生物/医药商业 公 司 研 究 老百姓（603883.SH） 2024 年 10 月 31 日 2024Q3 利润端承压，火炬项目稳步推进提毛利 ——公司信息更新报告 投资评级：买入（维持） | --- | --- | |---------------------------|---------------------------| | | | | 余汝意（分析师） | 巢舒然（联系人） | | yuruyi@kysec.cn | chaoshuran@kysec.cn | | 证书编号： S0790523070002 | 证书编号： S0790123110015 | 2024Q3 利润端承压，毛利率同比提升，维持"买入"评级 2024Q1-Q3 公司实现营收 162.32 亿元（同比+1.19%，下文皆为同比口径）；归母 净利润 6.30 亿元（-12.06%）；扣非归母净利润 6.07 亿元（-5.94%）。Q3 单季度， 公司实现营收 52.92 亿元（+1.18%）；归母净利润 1.27 亿元（-37.32%）；扣非归 母净利润 1.25 亿元（-19.10%）。从盈利能力来看，202 ...

证券代码：603883 证券简称：老百姓 老百姓大药房连锁股份有限公司 2024 年三季度报告解读会纪要 一、会议情况 （一）会议时间：2024 年 10 月 29 日 20:00-21:00 1、公司参会人员 董事长 谢子龙 总裁 王黎 财务总监 陈立山 董事会秘书 冯诗倪 2、机构参会人员 中信证券、东吴证券、中信建投、中金公司、浙商证券、海通证券、国盛证券、兴业证 券、招商证券、东北证券、广发证券、方正证券、汇丰、高盛、摩根大通、摩根士丹利、 国海证券、甬兴证券、国联证券、华创证券、东兴证券、民生证券、华泰证券、西部证 券、中邮证券、国金证券、东海证券、平安证券、华安证券、开源证券、中银国际、东 方证券、财通证券、长江证券、兴全基金、淡水泉、高毅资产、嘉实基金、农银汇理基 金、中信里昂、国投泰康、雪石资产、湖南医药发展基金、奶酪基金、北京金百镕投资、 上银、万丰友方、坚果投资、建信养老、青榕资产、上海君和、昆仑信托、资本集团、 博裕资本、森锦投资、前海开源基金、上海新伯霖私募、同犇投资、上海保银投资、中 信保诚基金、上海睿郡资产、上汽颀臻、中航基金、永安国富、相聚资本、富兰克林邓 普顿投资、尚诚资管、武 ...

Revenue and Profit Performance - Revenue for the first three quarters of 2024 reached RMB 16,232,148,089, an increase of 1.19% year-over-year[2] - Net profit attributable to shareholders of the listed company for the first three quarters of 2024 was RMB 630,147,823, a decrease of 12.06% year-over-year[2] - Revenue for the first three quarters of 2024 reached 16.232 billion yuan, a year-on-year increase of 1.19%[14] - Net profit attributable to shareholders of the listed company for the first three quarters of 2024 was 630 million yuan, a year-on-year decrease of 12.06%[14] - Total revenue for the first three quarters of 2024 reached RMB 16,232,148,089, a slight increase from RMB 16,041,526,841 in the same period of 2023[36] - Net profit attributable to parent company shareholders reached 630,147,823 yuan, a decrease from 716,560,499 yuan in the same period last year[37] - Total operating revenue for the first three quarters of 2024 was 18,599,452,504 yuan, compared to 18,265,401,747 yuan in the same period of 2023[39] Cash Flow and Financial Position - Net cash flow from operating activities for the first three quarters of 2024 was RMB 1,255,721,494, a decrease of 12.14% year-over-year[3] - Total assets as of the end of the third quarter of 2024 were RMB 21,211,311,937, a slight decrease of 0.09% compared to the end of the previous year[3] - Equity attributable to shareholders of the listed company as of the end of the third quarter of 2024 was RMB 6,961,742,913, an increase of 3.89% compared to the end of the previous year[3] - Net cash flow from operating activities was 1,255,721,494 yuan, down from 1,429,230,229 yuan in the previous year[39] - Total assets as of September 30, 2024, were RMB 21,211,311,937, slightly down from RMB 21,230,999,976 at the end of 2023[34] - Total liabilities as of September 30, 2024, were RMB 13,663,251,217, a decrease from RMB 13,941,960,115 at the end of 2023[35] - Shareholders' equity increased to RMB 7,548,060,720 as of September 30, 2024, up from RMB 7,289,039,861 at the end of 2023[35] - Cash and cash equivalents stood at RMB 2,099,006,221 as of September 30, 2024, up from RMB 1,974,984,513 at the end of 2023[32] - Inventory decreased to RMB 3,741,313,824 as of September 30, 2024, from RMB 4,152,484,967 at the end of 2023[32] - Long-term equity investments increased to RMB 85,220,294 as of September 30, 2024, up from RMB 67,821,191 at the end of 2023[34] - Cash and cash equivalents at the end of the period were 950,194,621 yuan, down from 1,028,321,991 yuan at the end of the previous year[41] - Total cash inflow from financing activities was 2,026,845,742 yuan, up from 1,100,273,193 yuan in the previous year[40] - Total cash outflow from investment activities was 464,461,047 yuan, compared to 706,820,762 yuan in the same period last year[40] - Net cash flow from investment activities was -439,382,336 yuan, compared to -343,615,820 yuan in the previous year[40] Store Operations and Expansion - The company had 15,591 stores as of September 30, 2024, including 10,300 directly operated stores and 5,291 franchised stores[19] - In the first three quarters of 2024, the company added 2,368 new stores, including 1,264 directly operated stores and 1,104 franchised stores[19] - The company closed 351 stores in the first three quarters of 2024, including 144 directly operated stores and 207 franchised stores[19] - Total number of stores reached 15,591, including 10,300 directly operated stores and 5,291 franchised stores[24] - In Q3 2024, the company added 2,368 new stores, with 1,264 directly operated stores and 1,104 franchised stores[24] - The company completed 3 acquisition projects in the reporting period, totaling 41 stores with a combined amount of 40.46 million yuan[22] - The company's stores in prefecture-level cities and below accounted for 77% of the total, with 80% of new stores in 2024 located in these areas[24] - The average preparation cycle for new directly operated stores in Q3 2024 was 40 days, a reduction of 5 days compared to the same period last year[24] Gross Profit and Margin - Gross profit margin for the first three quarters of 2024 was 33.87%, an increase of 1.36 percentage points year-on-year[14] - Revenue from retail business in the first three quarters of 2024 was 13.314 billion yuan, with a gross profit margin of 38.03%[15] - Revenue from the Chinese medicine business in the first three quarters of 2024 was 1.204 billion yuan, with a gross profit margin of 45.08%[17] - Revenue from non-drug products in the first three quarters of 2024 was 2.057 billion yuan, with a gross profit margin of 39.53%[17] - The gross profit margin for the first three quarters of 2024 was 33.87%, an increase of 1.36 percentage points year-on-year[25] - The company's promotional gross profit ROI was 1.49 in Q3 2024, a year-on-year increase of 6.1%[28] Online and Digital Performance - The company's online channel sales (including franchise) reached approximately 1.74 billion yuan in the first three quarters of 2024, a year-on-year increase of 16%[27] - The company's O2O and B2C sales rankings were fifth and third in the market, respectively, in Q3 2024[27] - The private domain mini-program sales increased by 22.6% year-on-year in Q3 2024, with DAU increasing by 118%[27] - The company has 12,555 O2O delivery service stores and 728 24-hour stores as of the end of the reporting period[27] - The total number of company members reached 97.17 million, with 14.65 million active members in Q3 2024 and over 3.1 million new registered members[27] Shareholder and Equity Information - The company's top shareholder, Laobaixing Pharmaceutical Group Co., Ltd., holds 26.12% of the shares, with 123,204,000 shares pledged[10] - Equity attributable to shareholders of the listed company as of the end of the third quarter of 2024 was RMB 6,961,742,913, an increase of 3.89% compared to the end of the previous year[3] - Shareholders' equity increased to RMB 7,548,060,720 as of September 30, 2024, up from RMB 7,289,039,861 at the end of 2023[35] Earnings and Return on Equity - Basic earnings per share for the third quarter of 2024 were RMB 0.17, a decrease of 37.31% year-over-year, primarily due to the decline in net profit attributable to shareholders[9] - The company's weighted average return on equity (ROE) for the first three quarters of 2024 was 9.14%, a decrease of 1.58 percentage points year-over-year[3] - Basic earnings per share (EPS) for the quarter were 0.83 yuan, compared to 0.94 yuan in the same period last year[38] - Total comprehensive income for the period was 743,726,347 yuan, a decrease from 820,172,473 yuan in the previous year[38] Non-Recurring Items and Impairment - Non-recurring gains and losses for the first three quarters of 2024 amounted to RMB 23,069,846, including government subsidies and gains from financial assets[6] - Total assets impairment loss was -10,447,829 yuan, compared to -2,659,467 yuan in the same period last year[37] Chronic Disease Management and Brand Exposure - The company's chronic disease management services have accumulated over 16.84 million records, 90.5 million self-tests, and 37.36 million follow-ups as of the end of the reporting period[30] - The company's brand exposure exceeded 1.4 billion times annually, with over 77.97 million views of brand videos on the self-media matrix in Q3 2024[31] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 were RMB 15,333,787,742, compared to RMB 15,075,343,081 in the same period of 2023[36] - Sales expenses increased to RMB 3,577,910,985 in the first three quarters of 2024, up from RMB 3,355,680,232 in the same period of 2023[36] - Management expenses rose to RMB 825,589,932 in the first three quarters of 2024, compared to RMB 703,469,470 in the same period of 2023[36] Inventory and Turnover - The inventory turnover days in Q3 2024 were 98 days, a decrease of 5 days year-on-year[25] - Inventory decreased to RMB 3,741,313,824 as of September 30, 2024, from RMB 4,152,484,967 at the end of 2023[32] Franchise and Alliance Business - The company's franchised business achieved a distribution sales volume of 1.639 billion yuan, a year-on-year increase of 7.5%[24] - The alliance business achieved a distribution sales volume of 280 million yuan, a year-on-year increase of 90.8%[24] Self-Owned Brand and Sales - The company's self-owned brand sales in directly operated stores reached 2.53 billion yuan, accounting for 21.9% of total sales, an increase of 2.4 percentage points year-on-year[25] Outpatient and Internet Prescription Services - The company has 5,347 stores (including 4,170 directly operated and 1,177 franchise) with outpatient coordination qualifications, accounting for 40.49% of directly operated stores[26] - The company has 4,191 stores (including 3,384 directly operated and 807 franchise) that can use internet prescriptions, accounting for 32.85% of directly operated stores[26]

证券代码：603883 证券简称：老百姓 公告编号：2024-068 老百姓大药房连锁股份有限公司 第五届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 （2）公司2024年第三季度的内容和格式符合中国证监会和上海证券交易所 的有关规定和要求，所包含的信息能全面、真实地反映公司在报告期内的经营 和财务管理状况。 一、监事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2024 年 10 月 19 日 发出召开第五届监事会第五次会议的通知，会议于 2024 年 10 月 29 日以现场方 式召开。会议应参与表决的监事 3 名，实际参与表决的监事 3 名。本次会议经 过了适当的通知程序，会议程序符合《中华人民共和国公司法》等有关法律法 规及《公司章程》的规定，会议及通过的决议合法有效。 二、监事会会议审议情况 会议审议并通过了如下议案： （一）审议通过《关于公司 2024 年第三季度报告的议案》 监事会认为： （1）公司2024年第三季度报告编制和审议符合法律、法规、《公司章程》 和 ...

证券代码：603883 证券简称：老百姓 公告编号：2024-069 老百姓大药房连锁股份有限公司 关于变更部分募集资金用途的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 重要内容提示： 老百姓大药房连锁股份有限公司（以下简称"公司"或"老百姓"）基于项 目实施情况和公司需求，经公司谨慎研究决策，为提升募集资金使用效率，拟将 原募集资金投资项目（以下简称"募投项目"）"企业数字化平台及新零售建设 项目"部分募集资金 6,600 万元用于实施新项目"老百姓大药房长沙 NDC 扩建 项目（一期）"。 "老百姓大药房长沙 NDC 扩建项目（一期）"总投资金额为 12,816 万元， 建设期 18 个月。 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"证监会"）《关于核准老百姓大药 房连锁股份有限公司非公开发行股票的批复》（证监许可[2021]2294 号）核准， 公司以非公开发行股票方式向特定投资者发行人民币普通股（A 股），募集资金 1/9 总额为人民币 1,740,453,673.80 元，扣除不含税发行费 ...

证券代码：603883 证券简称：老百姓 公告编号：2024-067 老百姓大药房连锁股份有限公司 第五届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 一、董事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2024 年 10 月 19 日发出召开第五届董事会第五次会议的通知，会议于 2024 年 10 月 29 日在公司 会议室以现场加通讯表决方式召开，本次董事会应参加表决的董事 9 名，实际 参加表决的董事 9 名。本次董事会由董事长谢子龙先生主持，董事会秘书等相 关人员列席会议。本次会议经过了适当的通知程序，会议程序符合有关法律法 规及《公司章程》的规定，会议及通过的决议合法有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 本议案已经公司第五届董事会战略与ESG委员会第二次会议审议通过，尚需 股东大会审议通过。 （一）审议通过《关于公司 2024 年第三季度报告的议案》 根据《公司法》《证券法》《上海证券交易所股票上市规则》等法律法规及 《公司章程》等规章制度， ...